Inovio stock holds in low single digits as losses weigh on outlook

Inovio stock trades in the low single digits as of August 28, 2026, with continued losses and negative earnings shaping expectations for the biotech company.

Inovio Pharmaceuticals, Inc. (ISIN US45773H2013) stock traded in the low single digits on August 28, 2026, as investors continued to weigh persistent losses and a negative earnings profile for the DNA medicine developer. Recent market data show the shares changing hands at $1.27, reflecting skepticism toward the company’s ability to translate its pipeline into sustainable profits. Recent quote data

Inovio stock price and valuation metrics

As of August 28, 2026, Inovio stock was quoted at $1.27, keeping the company firmly in small-cap territory. The shares have been trading at levels where traditional valuation metrics are distorted by ongoing losses, and the stock’s low price underscores how much execution risk investors are still pricing in. The same quote overview

Consensus data compiled by a financial portal indicate that the average 12-month price target for Inovio stands at $7.50, implying a large potential percentage gap between the current $1.27 quote and analyst expectations as of late August 2026. Analyst target overview

Earnings profile and analyst expectations

Inovio remains a loss-making company, which is reflected in its negative price-to-earnings ratio. A financial overview updated on August 28, 2026, reports that the company’s P/E ratio stands at -0.89, highlighting that the market is valuing the stock on expectations for future progress rather than current profitability. Financial summary

The same overview notes that earnings for Inovio are expected to improve over the coming year, with consensus anticipating a move from a per-share loss of $4.23 to a narrower per-share loss of $2.85. This projected $1.38 per-share reduction in the annual loss signals that analysts see some path toward better cost control or higher revenue, even if the company is still not projected to reach breakeven in the near term. INO earnings expectations

DNA medicine platform and pipeline focus

Inovio Pharmaceuticals focuses on developing DNA-based medicines designed to generate immune responses against cancer and infectious diseases. The company’s technology platform centers on delivering DNA plasmids into cells to prompt the production of specific antigens that can stimulate the immune system. This approach aims to combine the stability of DNA constructs with the flexibility to target different diseases by altering the encoded sequences.

Historically, Inovio’s programs have spanned multiple therapeutic areas, including oncology and viral infections, reflecting the versatility of its core technology. Clinical progress, regulatory feedback, and partnership activity remain key drivers for the long-term investment case, as successful late-stage data or commercial collaborations could help narrow the gap between current losses and future revenue potential.

INO stock and investor takeaway

For now, Inovio stock continues to trade on execution milestones and sentiment rather than on current profitability, with the $1.27 share price of August 28, 2026, standing far below the $7.50 average target indicated by analysts. The combination of a negative P/E ratio of -0.89 and projected improvement in earnings from a loss of $4.23 to a loss of $2.85 per share underlines how much depends on whether the company can convert its DNA medicine platform into commercially relevant products in the coming years.

Fact box

Company: Inovio Pharmaceuticals, Inc.

ISIN: US45773H2013

Ticker: INO

Exchange: Nasdaq

Price (as of August 28, 2026): $1.27 USD

Sector / Industry: Biotechnology